Clinical trials: Thrombi
Prevention of Venous Thromboembolism, Congenital Heart Disease
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
This is an observational study in which the data from children with congenital heart disease will be collected and studied. These children will include those who are prescribed rivaroxaban by their doctors after a heart surgery…
- Conditions
- Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure, Children
- Trial name
- NCT06193863
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Bayer
Operation Site Bleed
Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin
This trial is designed as a prospective, multi-center, randomized, feasibility clinical trial to evaluate the safety and efficacy of Thrombi-Gel as an absorbable surgical hemostat.
- Trial name
- Control (NCT00652314)
- Testing
- Thrombi-Gel
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Vascular Solutions LLC
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN Sub-study
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01182428
- Testing
- XIENCE V®/ XIENCE PRIME™, CYPHER SELECT
- Where
- 25 sites in Argentina, Austria and 13 more
- Volunteers
- 455 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Venous Thromboembolism, Arthroplasty, Replacement, Hip
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip…
- Trial name
- ONYX-3 (NCT00902928)
- Testing
- YM150, enoxaparin
- Where
- 156 sites in United States, Australia and 26 more
- Volunteers
- 1,992 people
- Sponsor
- Astellas Pharma Europe B.V.
Coronary Artery Disease
A Trial of Bare Metal Stent - Cobalt Chromium Versus Stent Coating With Sirolimus
The objective of this study is to evaluate the security issues and efficacy of coronary stenting Cobalt Chrome covered with sirolimus-eluting Cobalt Chrome platform in patients with coronary artery lesion.
- Trial name
- INSPIRON (NCT01093391)
- Testing
- DRUG ELUTING STENT, BARE METAL STENT
- Where
- 4 sites in Brazil
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Scitech Produtos Medicos SA
Pulmonary Embolism
VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial
The investigation is designed to verify that clinical use of the vena cava filter does not raise new questions of safety or effectiveness compared to currently-marketed permanent filters.
- Trial name
- NCT01112917
- Testing
- VenaTech Convertible Vena Cava Filter, Vena Cava Filter Conversion
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- B. Braun Interventional Systems, Inc
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA
This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and…
- Trial name
- NCT07140523
- Testing
- SRSD107, enoxaparin
- Where
- Czechia
- Volunteers
- 450 people
- Sponsor
- Sirius Therapeutics Co., Ltd.
Surgery, Central Line Associated Blood Stream Infections (CLABSI)
BIP CVC Clinical Safety and Performance Study
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
- Trial name
- NCT02811380
- Testing
- BIP CVC, Uncoated Standard CVC
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Bactiguard AB
Venous Thromboembolism
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
- Trial name
- DaPaR (NCT05536791)
- Testing
- Dabigatran Etexilate (DE)
- Where
- 6 sites in Germany, Netherlands and 2 more
- Sponsor
- Boehringer Ingelheim
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Ischemic Stroke
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
- Trial name
- NCT00499902
- Testing
- alfimeprase
- Where
- 22 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- ARCA Biopharma, Inc.
Venous Thrombosis
Switching Study From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when switching the treatment from warfarin to rivaroxaban.
- Trial name
- NCT01507051
- Testing
- Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Vitamin K (Konakion)
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Obesity, Overweight
A Study Investigating the Effects of Neprinol Study Product on Vascular Function
This open-label study investigated the effectiveness of Neprinol on maintaining healthy cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per day over a period of 12 weeks.
- Trial name
- NCT02862223
- Testing
- Neoprinol
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Hip Fractures
Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery
The purpose of this study is to evaluate the effects of enoxaparin on bleeding and venous blood clots in patients with hip fracture surgery.
- Trial name
- NCT00685958
- Testing
- enoxaparin (XRP4563)
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Sanofi
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals